Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Retained Earnings (2016 - 2025)

Regenxbio (RGNX) has 12 years of Retained Earnings data on record, last reported at -$687000.0 in Q4 2025.

  • For Q4 2025, Retained Earnings rose 7.29% year-over-year to -$687000.0; the TTM value through Dec 2025 reached -$687000.0, up 7.29%, while the annual FY2025 figure was -$687000.0, 7.29% up from the prior year.
  • Retained Earnings reached -$687000.0 in Q4 2025 per RGNX's latest filing, up from -$1.1 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$687000.0 in Q4 2025 and bottomed at -$1.1 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$423.6 million, with a median of -$390.4 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: skyrocketed 99.5% in 2021, then tumbled 24293.15% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$161.2 million in 2021, then tumbled by 173.86% to -$441.6 million in 2022, then skyrocketed by 99.0% to -$4.4 million in 2023, then soared by 83.27% to -$741000.0 in 2024, then rose by 7.29% to -$687000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$687000.0 in Q4 2025, -$1.1 billion in Q3 2025, and -$996.9 million in Q2 2025.